{"id":"vivitrol-medication-therapy","safety":{"commonSideEffects":[{"rate":"approximately 10-15%","effect":"Injection site reactions"},{"rate":"approximately 10%","effect":"Nausea"},{"rate":"approximately 5-10%","effect":"Headache"},{"rate":"approximately 5%","effect":"Fatigue"},{"rate":"approximately 5%","effect":"Insomnia"},{"rate":"approximately 5%","effect":"Anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vivitrol contains naltrexone, which competitively binds to opioid receptors (mu, delta, and kappa) and blocks the rewarding effects of opioids and alcohol. By preventing the pleasurable sensations associated with these substances, it reduces cravings and supports abstinence. The extended-release formulation provides sustained receptor blockade for approximately one month per injection.","oneSentence":"Vivitrol is a long-acting opioid antagonist that blocks opioid receptors to prevent euphoria and reduce cravings in opioid and alcohol use disorders.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:37.702Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder (prevention of relapse)"},{"name":"Alcohol use disorder (maintenance of abstinence)"}]},"trialDetails":[{"nctId":"NCT04599478","phase":"PHASE2, PHASE3","title":"Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2021-06-29","conditions":"Loss-of-control Eating, Obesity/Overweight","enrollment":160},{"nctId":"NCT07398404","phase":"PHASE1, PHASE2","title":"A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-07-01","conditions":"Obesity, Smoking Cessation, Bariatric Surgery Patients","enrollment":64},{"nctId":"NCT07224087","phase":"PHASE1","title":"Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-03-02","conditions":"Obesity, Smoking Cessation, Bariatric Surgery Patients","enrollment":20},{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":"Healthspan Improvement, Aging, Longevity","enrollment":30},{"nctId":"NCT07213466","phase":"PHASE4","title":"Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-19","conditions":"Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder","enrollment":100},{"nctId":"NCT07224009","phase":"PHASE2","title":"Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)","status":"NOT_YET_RECRUITING","sponsor":"University of Arkansas","startDate":"2026-03","conditions":"Metastatic Prostate Cancer","enrollment":60},{"nctId":"NCT06233799","phase":"PHASE3","title":"Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2024-07-01","conditions":"Methamphetamine-dependence, Methamphetamine Abuse","enrollment":360},{"nctId":"NCT04245423","phase":"NA","title":"The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2020-12-15","conditions":"Opioid-use Disorder, Mental Health Conditions","enrollment":567},{"nctId":"NCT07285473","phase":"PHASE2","title":"Low-Dose Naltrexone For ME/CFS: Dose-Finding","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Myalgic Encephalomyelitis/Chronic Fatigue Syndrome","enrollment":75},{"nctId":"NCT06845124","phase":"PHASE2","title":"A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence","status":"RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2025-07-22","conditions":"Alcohol Addiction, Alcoholism","enrollment":150},{"nctId":"NCT05338151","phase":"NA","title":"Promoting Alcohol Treatment Engagement Post-hospitalization","status":"RECRUITING","sponsor":"Yale University","startDate":"2022-09-13","conditions":"Alcohol Use Disorder","enrollment":450},{"nctId":"NCT04605081","phase":"PHASE2, PHASE3","title":"Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2022-01-10","conditions":"Loss-of-Control Eating, Obesity/Overweight","enrollment":100},{"nctId":"NCT06605703","phase":"PHASE4","title":"A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"WW International Inc","startDate":"2024-09-18","conditions":"Obesity, Overweight","enrollment":226},{"nctId":"NCT05028062","phase":"PHASE4","title":"Naltrexone in AUD Reward Drinkers","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-03-07","conditions":"Alcohol Use Disorder, Alcoholism","enrollment":60},{"nctId":"NCT07001371","phase":"NA","title":"Emotional Brain Training for Addiction Medicine Treatment - A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Loma Linda University","startDate":"2026-03","conditions":"Cannabis Use Disorder, Stimulant Use Disorder, Opioid Use Disorder","enrollment":54},{"nctId":"NCT03946111","phase":"PHASE2, PHASE3","title":"Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-08-07","conditions":"Binge-Eating Disorder, Obesity","enrollment":3},{"nctId":"NCT04464980","phase":"PHASE2","title":"Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2021-06-08","conditions":"Opioid Use Disorder (OUD)","enrollment":1516},{"nctId":"NCT06854614","phase":"PHASE4","title":"Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-03-01","conditions":"Obesity","enrollment":150},{"nctId":"NCT06845345","phase":"PHASE4","title":"Effect of Mediterranean Diet Combined With Intermittent Fasting on Liver Fibrosis Compared to Naltrexone/Bupropion in People With Cardiometabolic Risk Factors (MEDFAST-study)","status":"ENROLLING_BY_INVITATION","sponsor":"Carmen Dietvorst","startDate":"2025-04-14","conditions":"Diabetes Mellitus, Type 2, Liver Fibrosis, Liver Steatoses","enrollment":70},{"nctId":"NCT04345718","phase":"PHASE2, PHASE3","title":"EXHIT ENTRE Comparative Effectiveness Trial","status":"COMPLETED","sponsor":"Gavin Bart","startDate":"2021-08-09","conditions":"Substance Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe","enrollment":344},{"nctId":"NCT06306157","phase":"PHASE4","title":"Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital for Special Surgery, New York","startDate":"2024-01-02","conditions":"Complex Regional Pain Syndrome, Chronic Pain, Causalgia","enrollment":40},{"nctId":"NCT05748639","phase":"PHASE2, PHASE3","title":"Integrated Digital Intervention for Alcohol Use Disorder","status":"COMPLETED","sponsor":"Quit Genius","startDate":"2023-01-01","conditions":"Alcohol Use Disorder","enrollment":242},{"nctId":"NCT06774248","phase":"NA","title":"Expanding the Youth Opioid Recovery Support (YORS) Intervention for MOUD Adherence to Adolescents With OUD","status":"RECRUITING","sponsor":"Potomac Health Foundations","startDate":"2025-02-01","conditions":"Opioid Use Disorder","enrollment":80},{"nctId":"NCT06303778","phase":"NA","title":"Combining a Smartphone App With Medications to Manage Heavy Drinking","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-11-01","conditions":"Alcohol Use Disorder (AUD)","enrollment":330},{"nctId":"NCT06877572","phase":"","title":"Weight Loss Management in Endometrial Cancer Survivors","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2025-03-25","conditions":"Endometrial Cancer Survivors, Weight Management, Early Stage Endometrial Cancer","enrollment":50},{"nctId":"NCT05262270","phase":"PHASE2","title":"Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-04-18","conditions":"Cocaine Use Disorder","enrollment":427},{"nctId":"NCT07211724","phase":"NA","title":"Methamphetamine Use Disorder Support in Heart Failure Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"University of Southern California","startDate":"2025-11-01","conditions":"Heart Failure, Methamphetamine Use Disorder","enrollment":50},{"nctId":"NCT04173416","phase":"NA","title":"The Youth Opioid Recovery Support (YORS) Intervention","status":"RECRUITING","sponsor":"Potomac Health Foundations","startDate":"2020-02-17","conditions":"Opioid-use Disorder, Medication Adherence","enrollment":150},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT06374290","phase":"PHASE1","title":"Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2024-07-16","conditions":"Smoking Cessation","enrollment":2},{"nctId":"NCT05756764","phase":"","title":"Anti-obesity Pharmacotherapy and Inflammation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2023-06-01","conditions":"Obesity","enrollment":30},{"nctId":"NCT04817410","phase":"PHASE1","title":"ED Initiated Oral Naltrexone for AUD","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2021-09-28","conditions":"Alcohol Use Disorder","enrollment":30},{"nctId":"NCT04454411","phase":"PHASE2","title":"Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2022-08-01","conditions":"Opioid Dependence","enrollment":3},{"nctId":"NCT07092618","phase":"PHASE2, PHASE3","title":"Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation","status":"RECRUITING","sponsor":"AgelessRx","startDate":"2024-12-17","conditions":"Longevity, GLP-1, Geroscience","enrollment":150},{"nctId":"NCT06809166","phase":"PHASE4","title":"Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity","status":"RECRUITING","sponsor":"The Royal's Institute of Mental Health Research","startDate":"2024-07-04","conditions":"Obesity, Weight Loss, Weight Management","enrollment":40},{"nctId":"NCT05537935","phase":"PHASE4","title":"Low Dose Naltrexone for Pain in Patients With HIV","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-04-28","conditions":"Human Immunodeficiency Virus, Chronic Neuropathic Pain","enrollment":60},{"nctId":"NCT05189223","phase":"NA","title":"A Brief Values Intervention to Support Veterans in Early Buprenorphine Treatment","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-09-01","conditions":"Dependence, Opioid","enrollment":50},{"nctId":"NCT06021431","phase":"NA","title":"Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"BehaVR LLC","startDate":"2023-09-07","conditions":"Opioid Use Disorder","enrollment":128},{"nctId":"NCT05157698","phase":"PHASE2, PHASE3","title":"Pharmacological and Behavioral Treatment After Bariatric Surgery","status":"RECRUITING","sponsor":"Yale University","startDate":"2022-01-13","conditions":"Obesity","enrollment":160},{"nctId":"NCT05827159","phase":"PHASE3","title":"Emergency Department-Initiated Medications for Alcohol Use Disorder","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-08-17","conditions":"Alcohol Use Disorder","enrollment":240},{"nctId":"NCT03407638","phase":"NA","title":"PRimary Care Opioid Use Disorders Treatment (PROUD) Trial","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2018-02-28","conditions":"Opioid-use Disorder","enrollment":973759},{"nctId":"NCT04219540","phase":"PHASE4","title":"Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-01-07","conditions":"Opioid-use Disorder","enrollment":675},{"nctId":"NCT05011266","phase":"PHASE2, PHASE3","title":"Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder","status":"RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2023-04-18","conditions":"Opioid-use Disorder","enrollment":180},{"nctId":"NCT05919797","phase":"PHASE4","title":"Weight Loss Study: Genetics and Response to Naltrexone/Bupropion","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-06-08","conditions":"Obesity","enrollment":120},{"nctId":"NCT02330419","phase":"PHASE2","title":"Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2015-04","conditions":"Binge Drinking, HIV","enrollment":120},{"nctId":"NCT04678895","phase":"PHASE2","title":"Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2020-12-22","conditions":"Painful Diabetic Neuropathy","enrollment":35},{"nctId":"NCT06104280","phase":"","title":"Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-01-06","conditions":"Opioid Use Disorder, Sleep Disturbance","enrollment":200},{"nctId":"NCT04581603","phase":"PHASE4","title":"CBT-I Augmentation of Medication for Drinking in AUD","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2022-06-15","conditions":"Alcohol Use Disorder With Insomnia","enrollment":82},{"nctId":"NCT05812183","phase":"PHASE4","title":"Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-07-09","conditions":"Dyspnea, Quality of Life","enrollment":""},{"nctId":"NCT05092841","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A","status":"COMPLETED","sponsor":"Tasly GeneNet Pharmaceuticals Co., Ltd","startDate":"2021-09-28","conditions":"Charcot-Marie-Tooth Type 1A","enrollment":176},{"nctId":"NCT05042388","phase":"NA","title":"Mindfulness-Based Relapse Prevention to Improve Medication Assisted Treatment Adherence and Drug-use Outcomes for Opioid Use Disorder","status":"COMPLETED","sponsor":"West Chester University of Pennsylvania","startDate":"2021-08-01","conditions":"Opioid-use Disorder","enrollment":105},{"nctId":"NCT05043766","phase":"PHASE1","title":"Evaluation of Oral PF614 Relative to OxyContin (PF614-102)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2021-09-08","conditions":"Healthy Volunteers","enrollment":84},{"nctId":"NCT03431831","phase":"PHASE4","title":"Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-01","conditions":"Obesity","enrollment":86},{"nctId":"NCT04547985","phase":"PHASE4","title":"Naltrexone Treatment for Prolonged Grief Disorder (PGD)","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2021-01-05","conditions":"Prolonged Grief Disorder","enrollment":9},{"nctId":"NCT02926482","phase":"NA","title":"Intervention to Expand Opioid Use Disorder Treatment Pharmacotherapy Prescribers","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2016-10-26","conditions":"Opioid-use Disorder","enrollment":76},{"nctId":"NCT06426303","phase":"PHASE4","title":"Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder","status":"RECRUITING","sponsor":"Milky Kohno","startDate":"2024-05-02","conditions":"Alcohol Use Disorder","enrollment":100},{"nctId":"NCT04480554","phase":"PHASE2","title":"Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-01-30","conditions":"Opioid-use Disorder, HIV-1-infection, Immune Activation","enrollment":225},{"nctId":"NCT04575324","phase":"NA","title":"Project STAMINA (Syringe Service Telemedicine Access for Medication-assisted Intervention Through NAvigation)","status":"COMPLETED","sponsor":"Chestnut Health Systems","startDate":"2020-08-24","conditions":"Opioid-use Disorder","enrollment":275},{"nctId":"NCT06434818","phase":"PHASE2","title":"Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders","status":"RECRUITING","sponsor":"Evon Medics LLC","startDate":"2023-07-07","conditions":"Substance Use Disorders, Opioid Use Disorder, Alcohol Use Disorder","enrollment":300},{"nctId":"NCT03047005","phase":"PHASE2, PHASE3","title":"Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-08-28","conditions":"Binge-Eating Disorder, Obesity","enrollment":68},{"nctId":"NCT03063606","phase":"PHASE2, PHASE3","title":"Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-09-05","conditions":"Binge-Eating Disorder, Obesity","enrollment":31},{"nctId":"NCT00439049","phase":"","title":"Substance Abuse Pre-Treatment Screening Study","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2005-10","conditions":"Cocaine Abuse, Cocaine Dependence, Opiate Dependence","enrollment":7500},{"nctId":"NCT04662801","phase":"PHASE2, PHASE3","title":"Weight Regain Treatment Post-Bariatric Surgery","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-08-05","conditions":"Obesity, Overweight","enrollment":26},{"nctId":"NCT02885311","phase":"PHASE1, PHASE2","title":"Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2017-01","conditions":"Alcohol-Related Disorders, Alcohol Drinking, Alcoholism","enrollment":27},{"nctId":"NCT03976258","phase":"","title":"Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2017-07-14","conditions":"HIV Infection, Opioid-use Disorder, Cardiovascular Diseases","enrollment":190},{"nctId":"NCT04553263","phase":"EARLY_PHASE1","title":"Relapse Prevention in Stimulant Use Disorder","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-06-11","conditions":"Stimulant Use, Relapse, Cognitive Function","enrollment":""},{"nctId":"NCT04762537","phase":"NA","title":"Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2021-03-16","conditions":"Opioid-use Disorder","enrollment":415},{"nctId":"NCT04589130","phase":"PHASE4","title":"Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.","status":"UNKNOWN","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2021-02-01","conditions":"Obesity","enrollment":89},{"nctId":"NCT04587843","phase":"PHASE4","title":"A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery","status":"UNKNOWN","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2021-04-01","conditions":"Obesity","enrollment":18},{"nctId":"NCT04756128","phase":"PHASE2","title":"Impact of Colchicine and Low-dose Naltrexone on COVID-19","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2021-01-25","conditions":"Covid19","enrollment":142},{"nctId":"NCT03374956","phase":"PHASE3","title":"Individualized Obesity Pharmacotherapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-12-11","conditions":"Obesity","enrollment":193},{"nctId":"NCT01932801","phase":"PHASE2","title":"Harm Reduction With Pharmacotherapy (HaRP)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2013-08-01","conditions":"Alcohol Use Disorder","enrollment":308},{"nctId":"NCT03290391","phase":"PHASE4","title":"Linking Infectious and Narcology Care-Part II","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2018-09-19","conditions":"HIV Infection, Drug Use","enrollment":225},{"nctId":"NCT05087771","phase":"PHASE4","title":"In Hospital IM Naltrexone: A Pilot Study","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2022-03","conditions":"Alcohol Use Disorder","enrollment":""},{"nctId":"NCT04325802","phase":"PHASE2","title":"Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2022-12-31","conditions":"Atopic Dermatitis, Pruritus, Pruritus Chronic","enrollment":""},{"nctId":"NCT03045341","phase":"PHASE2, PHASE3","title":"Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-02-27","conditions":"Binge-eating Disorder, Obesity","enrollment":136},{"nctId":"NCT00053677","phase":"PHASE3","title":"Drug Treatment for Pathologic Gambling Disorder","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2002-12","conditions":"Gambling","enrollment":83},{"nctId":"NCT02268448","phase":"PHASE1","title":"Treatment of Chronic Itch in Atopic Dermatitis (Eczema): Nerve Function","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2015-07","conditions":"Cutaneous Nerves CNS Itch","enrollment":8},{"nctId":"NCT04270877","phase":"PHASE2","title":"Fibromyalgia and Naltrexone: The FINAL Study","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2021-01-06","conditions":"Fibromyalgia","enrollment":99},{"nctId":"NCT03711318","phase":"PHASE3","title":"Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2018-11-01","conditions":"Heroin Dependence","enrollment":8},{"nctId":"NCT04139213","phase":"PHASE2, PHASE3","title":"Medication Maintenance Therapy in Community Pharmacy Settings","status":"UNKNOWN","sponsor":"Lifespan","startDate":"2019-07-25","conditions":"Opioid-use Disorder","enrollment":250},{"nctId":"NCT05415891","phase":"NA","title":"The IMPROV Project: Improving Mental Health and Substance Use Treatment Provision (IMPROV) Among People Living With HIV (Human Immunodeficiency Virus) in Atlanta","status":"UNKNOWN","sponsor":"RTI International","startDate":"2022-06","conditions":"Mental Health Disorder, Substance Use Disorder, Stigmatization","enrollment":333},{"nctId":"NCT02537197","phase":"PHASE1","title":"The Effect of Regular Naltrexone Dosing on Disordered Gamblers","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2016-04","conditions":"Gambling","enrollment":35},{"nctId":"NCT04287790","phase":"","title":"Promoting Medications for Alcohol Use Disorder on the General Medicine Service","status":"TERMINATED","sponsor":"Yale University","startDate":"2020-01-01","conditions":"Alcohol Use Disorder","enrollment":67},{"nctId":"NCT03447782","phase":"PHASE1, PHASE2","title":"Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2018-07-23","conditions":"New Daily Persistent Headache (NDPH)","enrollment":45},{"nctId":"NCT05002946","phase":"PHASE1","title":"Pharmacokinetics of SP-104","status":"COMPLETED","sponsor":"Scilex Pharmaceuticals, Inc.","startDate":"2022-01-11","conditions":"Healthy","enrollment":18},{"nctId":"NCT02603471","phase":"NA","title":"Cell Phone Technology Targeting ART and Naltrexone Adherence and Alcohol Use","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2014-07","conditions":"HIV Infections, Alcohol Dependence","enrollment":35},{"nctId":"NCT04015115","phase":"NA","title":"Youth Opioid Recovery Support: Improving Care Systems","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2019-07-26","conditions":"Opioid-Related Disorders","enrollment":44},{"nctId":"NCT04365985","phase":"PHASE2","title":"Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19","status":"TERMINATED","sponsor":"Corewell Health East","startDate":"2020-04-29","conditions":"COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS)","enrollment":70},{"nctId":"NCT04409041","phase":"PHASE2","title":"Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-09-01","conditions":"Lichen Planopilaris, Frontal Fibrosing Alopecia","enrollment":43},{"nctId":"NCT01843023","phase":"PHASE4","title":"Extended Release Naltrexone for Opioid-Dependent Youth","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2013-06","conditions":"Drug Dependence","enrollment":288},{"nctId":"NCT01402492","phase":"PHASE2, PHASE3","title":"Cocaine Use Reduction With Buprenorphine","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-09","conditions":"Cocaine Dependence","enrollment":302},{"nctId":"NCT03762798","phase":"NA","title":"Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone","status":"WITHDRAWN","sponsor":"The Cleveland Clinic","startDate":"2018-11-19","conditions":"Substance Use Disorders, Substance Abuse, Substance Use","enrollment":""},{"nctId":"NCT01999946","phase":"PHASE4","title":"Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-06-27","conditions":"Heroin Dependence, Opioid-Related Disorders","enrollment":217},{"nctId":"NCT03078075","phase":"PHASE3","title":"Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-05-05","conditions":"Methamphetamine Use Disorder","enrollment":403},{"nctId":"NCT04154033","phase":"PHASE2","title":"Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2020-10-01","conditions":"Atopic Dermatitis, Pruritus, Dermatitis","enrollment":""},{"nctId":"NCT01415895","phase":"PHASE2","title":"Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back Pain","status":"COMPLETED","sponsor":"Annette C. Toledano MD","startDate":"2011-07","conditions":"Back Pain, Lower Back Pain, Cervical Pain","enrollment":78},{"nctId":"NCT04399395","phase":"PHASE4","title":"Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery","status":"WITHDRAWN","sponsor":"Oslo University Hospital","startDate":"2020-11-01","conditions":"Obesity","enrollment":""},{"nctId":"NCT04738773","phase":"PHASE2","title":"RCT for Gambling and Naltrexone, Using Use Eye-tracking Analysis to Predict Treatment Response","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2021-06-01","conditions":"Eye Tracking, Gambling Disorder, Naltrexone","enrollment":40},{"nctId":"NCT04575194","phase":"PHASE4","title":"Study of the Cardiometabolic Effects of Obesity Pharmacotherapy","status":"UNKNOWN","sponsor":"National and Kapodistrian University of Athens","startDate":"2020-09-08","conditions":"Obesity, Blood Pressure","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vivitrol (Medication Therapy)","genericName":"Vivitrol (Medication Therapy)","companyName":"Pacific Institute for Research and Evaluation","companyId":"pacific-institute-for-research-and-evaluation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vivitrol is a long-acting opioid antagonist that blocks opioid receptors to prevent euphoria and reduce cravings in opioid and alcohol use disorders. Used for Opioid use disorder (prevention of relapse), Alcohol use disorder (maintenance of abstinence).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}